NCT04575675View on ClinicalTrials.gov

Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy

PHASE4CompletedINTERVENTIONAL
Enrollment

78

Participants

Timeline

Start Date

May 29, 2020

Primary Completion Date

November 25, 2020

Study Completion Date

December 30, 2020

Conditions
HypotensionHeart Failure
Interventions
DRUG

Dapagliflozin

Dapagliflozin 10mg once daily

DRUG

Sacubitril-Valsartan

Sacubitril-Valsartan, maximal tolerated dosage

DRUG

Beta blocker

Cardio-selective beta-blocker, including carvedilol, bisoprolol, metoprolol or nebivolol

DRUG

Mineralocorticoid Receptor Antagonist

Mineralocorticoid receptor antagonist, including spironolactone or eplerenone

DEVICE

Cardiac resynchronization therapy and/or implantable cardioverter defibrillator

CRT-P, CRT-D or ICD if clinically indicated

Trial Locations (1)

Unknown

Cheng Hsin General Hospital, Taipei

All Listed Sponsors
lead

Cheng-Hsin General Hospital

OTHER

NCT04575675 - Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy | Biotech Hunter | Biotech Hunter